logo
Concrete goes green: UW and Microsoft use seaweed to create novel carbon-trapping cement

Concrete goes green: UW and Microsoft use seaweed to create novel carbon-trapping cement

Geek Wire08-07-2025
Sustainability: News about the rapidly growing climate tech sector and other areas of innovation to protect our planet. SEE MORE
Meng-Yen Lin, a member of Eleftheria Roumeli's lab at the University of Washington, mixes up seaweed-containing batter for making cement. (UW Photo)
Researchers have developed a novel solution for trapping carbon in concrete by blending a sustainable, easy-to-grow green seaweed into the industrial batter that makes cement, all without reducing its strength.
Scientists from the University of Washington and Microsoft Research used machine learning to expedite their experimentation, coming up with a solution that lowered the cement's global warming impacts by 21%
A study on their work is publishing online today in Matter, a science journal focused on materials science.
The research was led by Eleftheria Roumeli, a UW assistant professor in materials science and engineering, and Kristen Severson, a senior researcher with Microsoft Research. Roumeli previously developed an algae-based plastic that biodegrades in nature as quick as a banana peel.
The scientists wanted to tackle concrete given that it's responsible for between 8-11% of global carbon emissions. Cement, the key component of concrete, contributes to nearly all of that climate burden.
There are efforts worldwide to curb concrete's carbon footprint by using clean energy in generating the heat needed to product cement and by swapping in different ingredients to bind the cement such as industrial wastes like fly ash and furnace slag.
Scientists with the University of Washington and Microsoft Research used dehydrated seaweed to make a high-performing, lower-carbon cement. (UW Photo)
Roumeli and Severson turned to the seaweed given that it pulls carbon from the air and locks it away during photosynthesis. Others have tested the use of smaller algae, but the researchers were the first to choose a macroalgae called Ulva as their material because it has a more robust cellular structure they suspected could help reinforce the cement.
The scientists dehydrated the seaweed before incorporating it and were able to successfully use much higher amounts in the cement than previous demonstrations.
One of the difficulties in developing lower-carbon cement is the time required to make sure it's strong enough to be used in the construction of buildings, bridges and other infrastructure. Concrete gains strength over time, leading researchers to typically test the material after 28 days.
To speed up that process, the scientists developed a machine learning model that could predict how much stronger a sample would get over four weeks, allowing them to abandon underperforming strategies earlier in the process. The approach shaved 112 days off of experiment time. The model is adaptable and can be applied to other solutions for making greener cement.
'[T]his work establishes a framework with the potential to accelerate the design of sustainable cement with feasible experimental resources while satisfying critical performance requirements,' the authors wrote.
Other authors of the paper were Meng-Yen Lin and Paul Grandgeorge, who did the research as a graduate student and a post-doc, respectively, in Roumeli's lab. The publication is titled 'Closed-loop optimization using machine learning for the accelerated design of sustainable cements incorporating algal biomatter.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Unlocking Oncology Pipelines with Next-Gen AI and Functional Data, Upcoming Webinar Hosted by Xtalks
Unlocking Oncology Pipelines with Next-Gen AI and Functional Data, Upcoming Webinar Hosted by Xtalks

Yahoo

time25 minutes ago

  • Yahoo

Unlocking Oncology Pipelines with Next-Gen AI and Functional Data, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how to harness integrated functional multi-omics to enhance translational confidence and de-risk early-stage drug development for oncology programs. The featured speaker will discuss how to leverage key applications of AI and machine learning for extracting novel, actionable insights from complex multi-omic tumor datasets. Attendees will learn pragmatic, strategic approaches to integrate multi-omic and AI approaches into their own R&D pipelines for enhanced target identification and validation. The featured speaker will discuss the critical role of functional multi-omic data in overcoming current bottlenecks in oncology drug target discovery and development. TORONTO, Aug. 18, 2025 /PRNewswire/ -- How can functional multi-omic tumor data enable AI-driven target discovery and translational confidence? For pharma R&D and data science leaders, the demand for precise translational decisions has never been higher. However, the datasets currently available frequently fall short; they're fragmented, lack the necessary depth or don't accurately reflect real patient biology. This fundamental shortage of integrated, functional and clinically relevant data creates a significant bottleneck, impacting everything from the efficacy of internal AI models to the reliability of biomarker hypotheses. In this case-driven webinar, the featured speaker shares how a multi-disciplinary team harnessed a deeply profiled, functionalized tumor dataset to uncover and validate a novel oncology target: Vacuolar Protein Sorting–associated protein 4 (VPS4A/B). The discovery process began with a gene knockdown screen performed in 3D ex vivo cultures derived from clinically annotated patient-derived xenograft (PDX) tumors. Functional outcomes were integrated with deep transcriptomic data to train a machine learning model that accurately predicted VPS4 sensitivity. This approach led to the identification of CHAMP-002, a chemotype that triggered potent immunogenic responses and showed efficacy across multiple tumor types, including in combination with PD-1 blockade. This webinar will outline a framework for integrating deep tumor data into translational workflows that incorporate: AI/ML-ready datasets that are exportable, structured and grounded in fundamental tumor biology Integrated multi-modal layers, clinical history, omics, phenotypic data and drug response, all within a single, coherent system Data that maps to real-world patient cohorts, not abstract in vitro models Translational alignment for internal decision-making, target selection, biomarker validation and early development strategy Teams struggling with limitations with public datasets, failed to reproduce internal models or are looking to advance precision oncology initiatives, this webinar offers a window into how functionalized tumor data can drive more innovative R&D. Register for this webinar to learn how functional multi-omic data and AI integration can accelerate cancer target discovery. Join Michael Ritchie, PhD, MBA, Chief Commercial Officer, Champions Oncology, for the live webinar on Wednesday, September 3, 2025, at 11am EDT (4pm BST/UK). For more information, or to register for this event, visit Unlocking Oncology Pipelines with Next-Gen AI and Functional Data. ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit information about hosting a webinar visit Contact:Vera KovacevicTel: +1 (416) 977-6555 x371Email: vkovacevic@ View original content to download multimedia: SOURCE Xtalks

Cohesys Announces First-in-Human Use of Investigational BoneTape™ in Craniofacial Fracture Repair
Cohesys Announces First-in-Human Use of Investigational BoneTape™ in Craniofacial Fracture Repair

Yahoo

timean hour ago

  • Yahoo

Cohesys Announces First-in-Human Use of Investigational BoneTape™ in Craniofacial Fracture Repair

TORONTO, August 18, 2025--(BUSINESS WIRE)--Cohesys Inc., a Toronto-based medical device developer of resorbable fixation technologies, today announced that the first participants have undergone treatment with BoneTape™, an investigational device designed for the fixation of non-load-bearing craniofacial fractures. The procedures were completed as planned and mark the first clinical use of this drill- and screw-free fixation system. "Reaching this milestone is significant for Cohesys as we evaluate BoneTape's potential to offer a simpler, patient-friendly approach to fracture repair," said Dr. Michael Floros, CEO of Cohesys. "The data from this study will inform our regulatory strategy and commercialization pathway." "This marks an exciting step forward for the study, and it's a privilege to be part of an effort exploring new techniques in facial-fracture treatment," said Dr. Jeffrey A. Fialkov, MD, MSc, FRCSC, Head of the Division of Plastic and Reconstructive Surgery at Sunnybrook Health Sciences Centre, Associate Professor in the Department of Surgery at the University of Toronto, and Principal Investigator for the study. "BoneTape's hardware-free approach is intended to simplify surgery and may improve the recovery experience for patients." Device- and procedure-related risks—including infection, non-union, and re-operation—will be actively monitored throughout the study's follow-up period. Dr. Janaina Bortolatto, VP, Clinical Operations for Cohesys noted, "The completion of these first cases with BoneTape reflects the dedication of our team and our clinical partners. We are focused on gathering the clinical data needed to evaluate BoneTape for potential future use." BoneTape is applied with a handheld applicator that affixes the resorbable fixation device to bone surfaces without drilling or screws. The study will determine whether this design performs as intended, potentially sparing patients from device-related complications and the need for hardware-removal procedures. About CohesysCohesys Inc. develops advanced resorbable fixation solutions aimed at simplifying surgery and improving bone healing. BoneTape, the company's primary technology, is currently under clinical investigation. For more information, visit BoneTape™ is a trademark of Cohesys Inc. Regulatory StatusBoneTape is an investigational device; it is not licensed for commercial sale. Its use in this clinical study has been authorized by Health Canada under an Investigational Testing Authorization (ITA). Safety and effectiveness have not been established. Identifier: NCT06600854 View source version on Contacts Company Contact: info@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

bioAffinity Technologies Appoints New Members to Board of Directors
bioAffinity Technologies Appoints New Members to Board of Directors

Yahoo

timean hour ago

  • Yahoo

bioAffinity Technologies Appoints New Members to Board of Directors

Financial and Clinical Leaders Provide Significant Expertise for the Company's Commercial Growth SAN ANTONIO, Texas, August 18, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company advancing noninvasive diagnostics for the early detection of lung cancer and other diseases, today announced the appointment of Roberto Rios, CPA, and John J. Oppenheimer, M.D., to its Board of Directors. "Mr. Rios' business and financial expertise combined with Dr. Oppenheimer's clinical leadership will be invaluable as we increase sales of CyPath® Lung, develop companion diagnostics for asthma and COPD, and strengthen our financial position," said Maria Zannes, President and CEO of bioAffinity Technologies. Mr. Rios brings more than four decades of executive leadership in corporate finance and governance across industries including biotechnology, medical devices, and large-scale construction. He held financial leadership roles at ILEX Oncology, BioMedical Enterprises and Bartlett Cocke General Contractors and currently serves on the boards of CCC Group and Stem Cell Reserve. His proven track record in guiding companies through growth, capital strategy, and operational excellence will strengthen bioAffinity Technologies' financial foundation. Dr. Oppenheimer is the Director of Clinical Research at Pulmonary and Allergy Associates and Clinical Professor of Medicine at the University of Medicine and Dentistry of New Jersey-Rutgers. He is a leader in the diagnosis and treatment of asthma and COPD and an advisor to pharmaceutical companies focused on lung health. He has participated in more than 180 clinical studies and authored more than 260 publications and led or contributed to numerous clinical guidelines. Dr. Oppenheimer has served in leadership positions with the American Board of Allergy and Immunology, the American Academy of Allergy, Asthma & Immunology, and the American College of Allergy, Asthma & Immunology. His extensive clinical experience will help guide bioAffinity's scientific and clinical strategies, particularly in advancing its companion diagnostics in the pipeline for the growing asthma therapeutics market estimated at $26 billion. bioAffinity Technologies also announced that Gary Rubin stepped down from the Board of Directors for personal reasons and not due to any disagreement with the Company or its operations, policies or practices. "We are grateful to Gary for his valuable contributions to bioAffinity over the past seven years and appreciate his continued support," Ms. Zannes said. About CyPath® Lung CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the leadership, strengths and contributions Dr. Oppenheimer and Mr. Rios may bring to the Company in their role as members of the Board of Directors. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the leadership, strengths and contributions Dr. Oppenheimer and Mr. Rios may bring to the Company in their role as members of the Board of Directors and the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. View source version on Contacts bioAffinity Technologies Julie Anne OvertonDirector of Communicationsjao@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store